2-[4-(4-Propan-2-ylphenyl)piperazin-1-yl]ethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(4-Propan-2-ylphenyl)piperazin-1-yl]ethanol
• 化学式: C₁₅H₂₄N₂O
• 分子量: 248.36
• InChiKey: XTJYBHMYJMKJRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106436A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗药物，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。
• Bi-aryl meta-pyrimidine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20070259904A1

  公开（公告）日：2007-11-08

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供了具有一般结构（A）的联苯基间吡嘧啶化合物。本发明的吡嘧啶化合物能够抑制激酶，如Jak激酶家族成员以及其他特定的受体和非受体激酶。
• BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES
  申请人：Noronha Glenn

  公开号：US20110212077A1

  公开（公告）日：2011-09-01

  The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

  本发明提供了具有一般结构（A）的双芳基间位嘧啶化合物。本发明的嘧啶化合物能够抑制激酶，例如Jak激酶家族的成员以及其他特定的受体和非受体激酶。
• NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
  申请人：Cha Mi Young

  公开号：US20130116213A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.

  本发明涉及一种新型融合嘧啶衍生物，具有对酪氨酸激酶的抑制活性，以及一种药物组合物，其作为活性成分用于预防或治疗癌症、肿瘤、炎症性疾病、自身免疫疾病或免疫介导性疾病。
• NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR
  申请人：HANMI PHARM. CO., LTD.

  公开号：US20150299185A1

  公开（公告）日：2015-10-22

  Provided is a novel imidazopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.

  提供了一种新型咪唑吡啶衍生物，具有不可逆的酪氨酸激酶抑制活性，以及包含该衍生物的药物组合物，可用于预防或治疗炎症性疾病、自身免疫性疾病、增生性疾病或过度增生性疾病、免疫介导性疾病、癌症或肿瘤。